Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes
November 29, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
New Phase 3 RECOVERY Trial to Include Approximately 250 Participants Trial to Commence First Quarter 2019 With Topline Data Expected First Half 2020 NEW YORK, Nov. 29, 2018 (GLOBE NEWSWIRE) --...
Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
November 27, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to...
Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
November 09, 2018 07:30 ET
|
Tonix Pharmaceuticals Holding Corp.
New Phase 3 Trial of Tonmya® for the Treatment of PTSD to Commence First Quarter 2019 NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix or the...
Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya®
November 07, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S....
Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018
November 06, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Retrospective Analysis Revealed Clinically Meaningful Response to Tonmya® in Female PTSD Participants Overall and for Non-Combat-Related Traumas Experienced Within Nine Years Prior to Screening ...
Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference
November 01, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will...
Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting
October 31, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
New Phase 3 Trial of Tonmya® for the treatment of PTSD to Commence First Quarter 2019 Primary Endpoint of New Study will be Week 4 Change from Baseline in CAPS-5 NEW YORK, Oct. 31, 2018 (GLOBE...
Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018
October 29, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that it will be presenting findings and retrospective analyses from the Phase 3...
Tonix Pharmaceuticals to Present at the Dawson James Securities Small Cap Growth Conference
October 23, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will...
Tonix Pharmaceuticals to Present at the MicroCap Conference
September 26, 2018 13:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will...